Clinical Trial Update: Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MK-2206 with anastrozole, with or without goserelin acetate, in stage II-III breast cancer; the study was terminated and results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Anastrozole (Anastrozole)
• Goserelin acetate (goserelin)
• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor Positive, HER2/Neu Negative | Phase 2 | Status: TERMINATED | Results posted: 2018-05-08